Brazil and Turkey have declared different versions of the Sinovac vaccine to be effective, while Malaysia has formally signed the Sinovac vaccine agreement after declaring a state of emergency due to the worsening of the disease in its home country. But the purchase and supply are still under negotiation, and Malaysia’s science, technology and innovation minister, Khairy Jamaluddin, wrote on Twitter that his country would evaluate evidence from clinical trials before making a final decision on whether to buy.
Malaysia’s pharmaceutical company Pharmaniaga Bhd has signed an agreement with Sinovac to buy 14 million doses of the new crown vaccine for domestic production. Malaysia is also in talks with Cansino Biologics, another Chinese pharmaceutical company, and GameLeya Institute, a Russian company, to secure a total of 23.9m doses of the new crown vaccine. It also means that if Malaysia approves the vaccine programme, the supply of Chinese and Russian vaccines will surpass that of the US Pfizer and UK AstraZeneca.
As the outbreak continues to spread, Malaysian Prime Minister Muhyiddin Yassin announced a two-week action control order across five states and three federated territories, and the Malaysian head of state agreed to the Cabinet’s request for a state of emergency. Sin Chew Daily editor-in-chief Lim Swee Yuen wrote that the state of emergency would hit foreign investors’ confidence as administrative curfew for more than six months is very rare, with Malaysia’s parliament suspended and the government not subject to adequate checks and balances, and investors worried about no safeguards. He called on the Malaysian government to introduce another aid package and incentives to support small and medium-sized enterprises.
Experience when it comes to China’s resistance to disease, Lin Ruiyuan thinks the government can’t depend entirely on the action control curve flatten infection, must follow the way that Chinese resistance to disease, early detection, report, isolation and treatment, including large-scale screening, isolation of asymptomatic patients, eliminate risk to stop the spread of foreign labor will be coronavirus widely in the community. Malaysia, “he wrote,” 15 special treatment will be coronavirus hospital bed utilization rate more than 70%, the central hospital and medical center at the university of malaya, Kuala Lumpur beds is 100% fully use, no empty bed, so the government should make full use of action control, unblock clogged in medical system as soon as possible, otherwise will be futile wu reactive.”
While Jamaluddin said the effectiveness of clinical trials needed to be evaluated, he said Sinovac’s vaccine has been approved by Indonesia, Brazil, Turkey and other countries, and Malaysia will move forward with the implementation of the vaccination program as soon as possible. Malaysia’s defence and health ministers both attended the signing ceremony with Sinovac in Kuala Lumpur. Jamaluddin said, “The Malaysian government is pleased to see the signing of the Covid-19 vaccine cooperation agreement between the two companies, which will not only help Malaysia procure enough new crown vaccines, but also help improve the R&D and production level. The Malaysian government is satisfied with the clinical trial data of Sinovac vaccine and will reach a purchase agreement in the near future. It is hoped that the drug regulatory authorities will approve the use of Sinovac vaccine as soon as possible.”
Malaysia has seen more than 2,000 new cases a day for a week and Muhyiddin warned that he had a duty as prime minister to suspend elections temporarily to protect people’s lives and national security. If nothing is done, he said, there could be an additional 8,000 cases a day by the end of May. Notably, he described China as the voice of rational moderation during the Covid-19 epidemic, referring to China’s call for countries not to overdo their emergency crisis mitigation efforts to affect domestic economic activity. He reiterated Malaysia’s position as a key supporter of a volatile trading system, calling for a rejection of protectionism and unilateralism, and a commitment to cross-border mobility of goods and services.
Malaysia’s health director-general, Dr Tan Sri Dr Noor Hisham Abdullah, had previously exposed false information about the unsafe use of the Chinese-made new champion vaccine candidate, and highlighted China’s successful track record in producing vaccines for other diseases besides Covid-19. He also noted that China has become a provider of pre-certified vaccines launched by the World Health Organization (WHO) for influenza, polio, hepatitis A and Japanese encephalitis.
According to the original plan, Malaysia will buy high-end from Taiwan company research and development of new vaccines, but high-end vaccine said in accordance with the previously signed agreement, Malaysia MGB subsidiary Metronic Medicare Sdn Bhd (MMSB) should be done in November 27, deposit 1.5 million dollars remittance, but MGB company told delaying the remittance of bank operation factors, the two sides agreed to delay until December 31 of the date of the remittance. However, as of December 31, high-end vaccine has not received the remittance, and the escrow account could not be set up in time. High-end vaccine said that in order to protect the interests of the company, MOA first terminated the agreement in accordance with the agreement, and in the future, it will evaluate the most appropriate strategy to promote the business in Malaysia.